Table 1.
Patient, disease, and treatment characteristics
| No. | % | |
|---|---|---|
| Total number of patients | 1,020 | - |
| Age, years: median (IQR) | 67 (59–73) | |
| Gender | ||
| Male | 802 | 78.6 |
| Female | 211 | 20.7 |
| Missing | 7 | 0.7 |
| Ethnicity | ||
| Not Hispanic/latino, White | 831 | 81.5 |
| Not Hispanic/latino, Black | 29 | 2.8 |
| Hispanic or latino | 81 | 7.9 |
| Other or mixed | 22 | 2.2 |
| Missing | 57 | 5.6 |
| Smoking history | ||
| Current smoker | 220 | 21.5 |
| Former smoker | 359 | 35.2 |
| Never smoker | 226 | 22.2 |
| Missing | 215 | 21.1 |
| Primary tumour location | ||
| Bladder | 828 | 81.2 |
| Renal pelvis or ureter | 165 | 16.2 |
| Urethra | 6 | 0.6 |
| Missing | 21 | 2.0 |
| Histology | ||
| Pure UC | 923 | 90.5 |
| UC with divergent histologies | 79 | 7.7 |
| Missing | 18 | 1.8 |
| BMI, Kg/m2: median (IQR) | 26.3 (23.6–29.1) | |
| ECOG-Performance Status | ||
| 0 | 303 | 29.7 |
| 1 | 392 | 38.4 |
| 2 | 110 | 10.8 |
| >2 | 20 | 2.0 |
| Missing | 195 | 19.1 |
| Baseline Haemoglobin, gr/dL: median (IQR) | 12.2 (10.9–13.5) | |
| Baseline WBC, ×103/μL: median (IQR) | 8.0 (6.3–10.3) | |
| Prior peri-operative systemic therapy | 171 | 16.8 |
| Time from end peri-operative chemotherapy to start first-line, months: median (IQR) | 11.0 (4.8–24.5) | |
| ≤12 months | 71 | 41.5 |
| >12 months | 61 | 35.7 |
| Undetermined | 39 | 22.8 |
| Number of metastatic sites | ||
| 1 | 415 | 40.7 |
| 2 | 306 | 30.0 |
| ≥3 | 254 | 24.9 |
| Missing | 45 | 4.4 |
| Site of metastases | ||
| Pelvic lymph-nodes | 391 | 38.3 |
| Retroperitoneal lymph-nodes | 305 | 29.9 |
| Other lymph-nodes | 183 | 17.9 |
| Lung | 258 | 25.3 |
| Bone | 256 | 25.1 |
| Liver | 189 | 18.5 |
| Pelvic soft tissue | 127 | 12.5 |
| Peritoneum | 30 | 2.9 |
| Brain | 16 | 1.6 |
| Other | 152 | 14.9 |
| Type of first-line chemotherapy | ||
| Cisplatin-based combination | 639 | 62.6 |
| Gemcitabine and cisplatin | 429 | 67.2 |
| MVAC or DD-MVAC | 167 | 26.1 |
| Taxane, cisplatin, and gemcitabine | 9 | 1.4 |
| Other | 34 | 5.3 |
| Carboplatin-based combination | 381 | 37.4 |
| Gemcitabine and carboplatin | 307 | 80.6 |
| Taxane and carboplatin | 39 | 10.2 |
| Taxane, carboplatin, and gemcitabine | 15 | 3.9 |
| Other | 20 | 5.3 |
| Response to first-line chemotherapy | Total: 813 | |
| CR | 85 | 10.5 |
| PR | 285 | 35.1 |
| SD | 215 | 26.4 |
| PD | 228 | 28.0 |
Abbreviations: CR: complete response; ECOG: Eastern Cooperative Oncology Group; IQR: interquartile range; (DD)-MVAC: (dose-dense)-methotrexate, vinblastine, doxorubicin, cisplatin; PD: disease progression; PR: partial response; SD: stable disease; UC: urothelial carcinoma; WBC: white blood cell count.